Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00285
|
|||||
| Drug Name |
Silodosin
|
|||||
| Synonyms |
(R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; CHEMBL24778; CUZ39LUY82; KAD 3213; KAD-3213; KMD 3213; KMD-3213; Q-102517; Rapaflo; Rapflo; Silodosin-d6; Silodyx; UNII-CUZ39LUY82; Urief; Urorec
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Benign prostatic hyperplasia [ICD11: GA90] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H32F3N3O4
|
|||||
| Canonical SMILES |
CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
|
|||||
| InChI |
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
|
|||||
| InChIKey |
PNCPYILNMDWPEY-QGZVFWFLSA-N
|
|||||
| CAS Number |
CAS 160970-54-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 495.5 | Topological Polar Surface Area | 97 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103194366
, 104046714
, 109693099
, 11056891
, 114157936
, 12014894
, 126623000
, 126665711
, 128939931
, 131300819
, 134339064
, 134340151
, 134342132
, 135252710
, 135368407
, 135650458
, 135916576
, 137248544
, 142093997
, 14810706
, 14835413
, 152258092
, 152344280
, 160646931
, 162011672
, 162172235
, 162223757
, 163884568
, 164765008
, 164777753
, 172085148
, 174527805
, 175266679
, 175427058
, 175612190
, 179150028
, 184816547
, 187071911
, 198991703
, 202821102
, 211536181
, 223392962
, 223484371
, 39341745
, 57359519
, 7849027
, 7979683
, 80176928
, 92098546
, 99299508
|
|||||
| ChEBI ID |
CHEBI:135929
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MDR3 | Transporter Info | Multidrug resistance protein 3 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Silodosin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. | |||||
| 3 | The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2013;28(3):239-43. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.